236 related articles for article (PubMed ID: 19958752)
1. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia.
Qian Z; Joslin JM; Tennant TR; Reshmi SC; Young DJ; Stoddart A; Larson RA; Le Beau MM
Chem Biol Interact; 2010 Mar; 184(1-2):50-7. PubMed ID: 19958752
[TBL] [Abstract][Full Text] [Related]
2. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans.
Larson RA; Le Beau MM
Chem Biol Interact; 2005 May; 153-154():187-95. PubMed ID: 15935816
[TBL] [Abstract][Full Text] [Related]
3. Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice.
Stoddart A; Fernald AA; Wang J; Davis EM; Karrison T; Anastasi J; Le Beau MM
Blood; 2014 Feb; 123(7):1069-78. PubMed ID: 24381225
[TBL] [Abstract][Full Text] [Related]
4. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia.
Pedersen-Bjergaard J; Pedersen M; Roulston D; Philip P
Blood; 1995 Nov; 86(9):3542-52. PubMed ID: 7579462
[TBL] [Abstract][Full Text] [Related]
5. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.
Mauritzson N; Albin M; Rylander L; Billström R; Ahlgren T; Mikoczy Z; Björk J; Strömberg U; Nilsson PG; Mitelman F; Hagmar L; Johansson B
Leukemia; 2002 Dec; 16(12):2366-78. PubMed ID: 12454741
[TBL] [Abstract][Full Text] [Related]
6. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis.
Christiansen DH; Andersen MK; Pedersen-Bjergaard J
J Clin Oncol; 2001 Mar; 19(5):1405-13. PubMed ID: 11230485
[TBL] [Abstract][Full Text] [Related]
7. A new recurrent translocation, t(5;11)(q35;p15.5), associated with del(5q) in childhood acute myeloid leukemia. The UK Cancer Cytogenetics Group (UKCCG).
Jaju RJ; Haas OA; Neat M; Harbott J; Saha V; Boultwood J; Brown JM; Pirc-Danoewinata H; Krings BW; Müller U; Morris SW; Wainscoat JS; Kearney L
Blood; 1999 Jul; 94(2):773-80. PubMed ID: 10397745
[TBL] [Abstract][Full Text] [Related]
8. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases.
Merlat A; Lai JL; Sterkers Y; Demory JL; Bauters F; Preudhomme C; Fenaux P
Leukemia; 1999 Feb; 13(2):250-7. PubMed ID: 10025899
[TBL] [Abstract][Full Text] [Related]
9. Genetics of therapy-related myelodysplasia and acute myeloid leukemia.
Pedersen-Bjergaard J; Andersen MK; Andersen MT; Christiansen DH
Leukemia; 2008 Feb; 22(2):240-8. PubMed ID: 18200041
[TBL] [Abstract][Full Text] [Related]
10. Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q).
Kanagal-Shamanna R; Yin CC; Miranda RN; Bueso-Ramos CE; Wang XI; Muddasani R; Medeiros LJ; Lu G
Cancer Genet; 2013; 206(1-2):42-6. PubMed ID: 23357231
[TBL] [Abstract][Full Text] [Related]
11. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM
Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923
[TBL] [Abstract][Full Text] [Related]
12. [Genetic defects of chromosome 5q and 7q in myeloid neoplasms].
Hosono N
Rinsho Ketsueki; 2019; 60(7):800-809. PubMed ID: 31391370
[TBL] [Abstract][Full Text] [Related]
13. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera: single center experience and review of literature.
Swolin B; Rödjer S; Westin J
Ann Hematol; 2008 Jun; 87(6):467-74. PubMed ID: 18351338
[TBL] [Abstract][Full Text] [Related]
14. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
[TBL] [Abstract][Full Text] [Related]
15. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH.
Schoch C; Haferlach T; Bursch S; Gerstner D; Schnittger S; Dugas M; Kern W; Löffler H; Hiddemann W
Genes Chromosomes Cancer; 2002 Sep; 35(1):20-9. PubMed ID: 12203786
[TBL] [Abstract][Full Text] [Related]
16. Loss of 5q in myeloid malignancies - A gain in understanding of biological and clinical consequences.
Venugopal S; Mascarenhas J; Steensma DP
Blood Rev; 2021 Mar; 46():100735. PubMed ID: 32736878
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of c-myc gene accompanied by PU.1 deficiency in radiation-induced acute myeloid leukemia in mice.
Hirouchi T; Takabatake T; Yoshida K; Nitta Y; Nakamura M; Tanaka S; Ichinohe K; Oghiso Y; Tanaka K
Exp Hematol; 2008 Jul; 36(7):871-85. PubMed ID: 18375040
[TBL] [Abstract][Full Text] [Related]
18. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.
Smith SM; Le Beau MM; Huo D; Karrison T; Sobecks RM; Anastasi J; Vardiman JW; Rowley JD; Larson RA
Blood; 2003 Jul; 102(1):43-52. PubMed ID: 12623843
[TBL] [Abstract][Full Text] [Related]
19. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
Volkert S; Kohlmann A; Schnittger S; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 May; 53(5):402-10. PubMed ID: 24493299
[TBL] [Abstract][Full Text] [Related]
20. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]